Betifisolimab

• Description :

  Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research[1].

• Product Name Alternative :

  MSB-2311

• UNSPSC :

  12352203

• Target :

  PD-1/PD-L1

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/betifisolimab.html

• Purity :

  99.04

• Solubility :

  10 mM in DMSO

• Smiles :

  [Betifisolimab]

• Molecular Weight :

  (146.14 kDa)

• References & Citations :

  [1]Xichun Hu, et al. MSB2311, an anti-programmed death-ligand 1 antibody, in advanced solid tumors and hematological malignancies: Safety and tolerability, early anti-cancer activities from a phase I study in Chinese patients. Journal of Clinical Oncology 38, no. 15_suppl.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 1

• CAS Number :

  [2460539-60-8]